126
Objectives:
We aim to determine the benefits of ICT in OSCC
therapy by performing a systematic review using the cumulative
meta-analysis technique.
Methods:
A literature search identified for RCTs compar-
ing OSCC patients who received ICT against those without.
Log-hazard ratio, and relative risk were used for comparison. Het-
erogeneity was determined using the I2 statistic package. Data
analysis was performed for endpoints including overall survival
(OS), disease-free survival (DFS), locoregional recurrence (LRR)
and distant metastasis (DM).
Findings:
27 randomised trials were eligible for analysis
(
n
= 2872 patients). The shortest median follow-up was 15 months
whereas the longest was 11.5 years. ICT does not improve OS
(HR = 0.947; 95% CI 0.85–1.05;
P
= 0.318), DFS (RR = 1.05;
95% CI 0.92–1.21;
P
= 0.462) and DM (RR = 0.626; CI 95%
0.361–1.086;
P
= 0.096) compared to locoregional treatment
alone. However, there was a significant improvement to LRR
(RR = 0.778; 95% CI 0.622–0.972;
P
= 0.027).
Conclusion:
There is no evidence ICT improves survival out-
comes for OSCC patients which can be effectively visualised
through a cumulative meta-analysis approach. However, ICT
reduces locoregional recurrence of OSCC, whichmay need further
verification.
http://dx.doi.org/10.1016/j.ijom.2017.02.439Must we remove submandibular glands during neck
dissection in oral squamous cell carcinoma patients?
K.H. Lee
∗
, K.C. Chen, T.Y. Wong
Division of Oral and Maxillofacial Surgery, Department of
Stomatology, National Cheng Kung University Hospital, Tainan,
Chinese Taipei
Background:
During the past years, treatment of oral squamous
cell carcinoma (OSCC) patients including ablative surgery of the
tumour and neck dissection to remove possible metastatic lymph
nodes. In the past, we usually removed submandibular glands at the
same time during neck dissection procedure. Patient often suffered
from xerostomia after the ablative surgery.
Objectives:
However, in our experiences, submandibular gland
metastasis was rare. We could not help asking: “Could we spare
the gland during neck dissection procedure?” And if we plan to
replace present treatment policy, we must have enough evidence
to support our idea. But the true metastasis rate of submandibular
gland is still lack of research evidence by now.
Methods:
In this study, 146 OSCC patients treated in NCKU from
2013 to 2016 were included. All of them received neck dissection
unilaterally or bilaterally during ablative surgery. The pathological
reports of these patients were reviewed and statistic analysed.
Findings and Conclusion:
Hardly any submandibular gland
metastasis was recorded, even with level Ib neck lymph node
metastasis. Only two patients with very advanced tumour were
found with submandibular gland involvement. The result supports
our idea that submandibular gland sparing during neck dissection
in OSCC patients is feasible and may improve the life of quality
of our patients after ablative surgery.
http://dx.doi.org/10.1016/j.ijom.2017.02.440A potential solution to immunosuppression of the tumour
microenvironment: results of a phase 1 clinical trial of
anti-OX-40 in head and neck squamous cell carcinoma
R. Leidner
∗
, M. Crittenden, M. Gough, B.A. Fox,
A.D. Weinberg, E.J. Dierks, R.B. Bell
Providence Cancer Center, Portland, OR, United States
Background:
Cancer immunotherapy utilises the host immune
system to attack tumour cells by an activated immune response.
Head and neck SCC (HNSCC) release suppressive factors that
impair the immune system. OX40 is a potent costimulatory path-
way that when triggered can enhance T-cell memory, proliferation
and antitumour activity in patients with metastatic cancer.
Objectives:
To determine the maximum tolerated dose, toxicity,
immunologic activity, and potential clinical activity following one
cycle of anti-OX40 treatment.
Methods:
Participants received a single cycle of anti-OX40 given
intravenously on days one, three and five. There were three cohorts
of 10 patients each. Patients in cohort 1 received one cycle of
0.1 mg/kg; cohort 2, 0.4 mg/kg; and cohort 3, 2 mg/kg of the mAb.
Tumour tissues and peripheral blood are collected during resection
for measurements of tumour infiltrating immune cell populations
using flow cytometry and immunohistochemistry that may corre-
late with changes induced by anti-OX40 administration.
Results:
The toxicity profile was mild. Of the 30 patients treated,
12 patients displayed regression of individual tumour deposits
in lung, subcutaneous sites or lymph nodes; and six others had
stable metastatic disease for up to one year after anti-OX40 treat-
ment. Immunologic changes were observed at all dose levels with
significant proliferation of CD4+ and CD8+ central and effector
memory T-cell populations in both the tumour microenvironment
and circulation.
Conclusion:
There is significant expression of OX40 in the TIL
of patients with HNSCC. Furthermore, we noted co-expression of
OX40 with PD1 and CTLA-4 in a majority of tumour specimens,
especially within the T-reg population.
http://dx.doi.org/10.1016/j.ijom.2017.02.441Global incidence of oral and oropharyngeal cancer in young
adults: a systematic review
F. Leusink
∗
, F. Leusink, A. Hussein, M. Helder, H. de Vet,
T. Forouzanfar
Department of Oral and Maxillofacial Surgery and Oral
Pathology, University Hospital Vrije Universiteit
Amsterdam/ACTA, Amsterdam, The Netherlands
Background:
Oral and oropharyngeal squamous cell carcinoma
(OOPSCC) is typically regarded as a disease of elderly people.
However, increasing numbers of patients worldwide with OOP-
SCC at a younger age (40–45 years) have been reported recently.
Objectives:
This systematic reviewbrings together 77 studies con-
ducted over four decades to look at geographical variations and
trends worldwide in incidence of OOPSCC in young adults.
Methods:
The authors searched PubMed and Google scholar
databases from 1975 to June 2016. Studies were included if they
reported incidence rate of oral and oropharynx cancer separately
for age cut-off less than 45 years.




